Omeros announces full exercise and closing of underwriter’s option to purchase additional shares

Seattle--(business wire)--omeros corporation (nasdaq: omer) (“omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, announced today the full exercise and closing of the sale of 572,518 shares of common stock to t
OMER Ratings Summary
OMER Quant Ranking